Literature DB >> 18197418

Patterns of doramectin tissue residue depletion in parasitized vs nonparasitized lambs.

Rubén Pérez1, Cristina Palma, Maria José Nuñez, Ignacio Cabezas.   

Abstract

The effect of gastrointestinal parasitism on patterns of edible tissue depletion of doramectin was studied in greyface Suffolk lambs. Twelve weight-matched pairs of lambs were allocated into group I (nonparasitized, pretreated with three administrations of 5 mg/kg fenbendazole) and group II (parasitized, did not receive anthelmintic treatment). Both groups were maintained together under similar conditions for 70 days, when they were treated with a subcutaneous dose of 0.2 mg/kg bw doramectin. At 7, 14, 21, and 28 days after doramectin administration, three lambs from each group were slaughtered and samples of liver, kidney, muscle, and fat were obtained. Pre-treatment with fenbendazole significantly reduced the nematode fecal egg count and significantly increased lamb body weight compared to the parasitized group. Doramectin was detected in all of the tissues up to 28 days post-treatment. Significantly higher and more persistent doramectin concentrations were found in the nonparasitized lambs compared to the parasitized animals. Considering the EMEA maximum residue limits for doramectin in fat, the calculated withdrawal period for the healthy lambs (43 days) was significantly higher than that for the parasitized animals (26 days).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18197418     DOI: 10.1007/s00436-008-0874-y

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  20 in total

1.  Comparative plasma disposition kinetics of ivermectin, moxidectin and doramectin in cattle.

Authors:  C Lanusse; A Lifschitz; G Virkel; L Alvarez; S Sánchez; J F Sutra; P Galtier; M Alvinerie
Journal:  J Vet Pharmacol Ther       Date:  1997-04       Impact factor: 1.786

2.  The influence of parasitism on the pharmacokinetics of moxidectin in lambs.

Authors:  Anne Lespine; Jean-François Sutra; Jacques Dupuy; Michel Alvinerie; Gilles Aumont
Journal:  Parasitol Res       Date:  2004-05-01       Impact factor: 2.289

3.  Binding characteristics of ivermectin in plasma from collie dogs.

Authors:  S P Rohrer; D V Evans
Journal:  Vet Res Commun       Date:  1990       Impact factor: 2.459

Review 4.  Nutrition-parasite interaction.

Authors:  R L Coop; I Kyriazakis
Journal:  Vet Parasitol       Date:  1999-08-01       Impact factor: 2.738

5.  Gastrointestinal parasitism reduces the plasma availability of doramectin in lambs.

Authors:  Rubén Pérez; Cristina Palma; Marcia Araneda; Ignacio Cabezas; Luis Rubilar; Margarita Arboix
Journal:  Vet J       Date:  2005-10-25       Impact factor: 2.688

Review 6.  The effect of subclinical parasitism in sheep.

Authors:  A R Sykes
Journal:  Vet Rec       Date:  1978-01-14       Impact factor: 2.695

7.  Pharmacokinetics and bioequivalence of parenterally administered doramectin in cattle.

Authors:  M A Nowakowski; M J Lynch; D G Smith; N B Logan; D E Mouzin; J Lukaszewicz; N I Ryan; R P Hunter; R M Jones
Journal:  J Vet Pharmacol Ther       Date:  1995-08       Impact factor: 1.786

Review 8.  Analytical strategies for the screening of veterinary drugs and their residues in edible products.

Authors:  M M Aerts; A C Hogenboom; U A Brinkman
Journal:  J Chromatogr B Biomed Appl       Date:  1995-05-05

9.  The pharmacodynamics of ivermectin in sheep and cattle.

Authors:  J A Bogan; Q A McKellar
Journal:  J Vet Pharmacol Ther       Date:  1988-09       Impact factor: 1.786

10.  Protein binding and ivermectin estimations in patients with onchocerciasis.

Authors:  P O Okonkwo; J E Ogbuokiri; E Ofoegbu; U Klotz
Journal:  Clin Pharmacol Ther       Date:  1993-04       Impact factor: 6.875

View more
  1 in total

Review 1.  Confounding factors affecting faecal egg count reduction as a measure of anthelmintic efficacy.

Authors:  Eric R Morgan; Carlos Lanusse; Laura Rinaldi; Johannes Charlier; Jozef Vercruysse
Journal:  Parasite       Date:  2022-04-07       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.